SCHEMBL1560168

SCHEMBL1560168

CCc1cccc(CC)c1NC(=O)c1nn(C)c2c1CCc1cnc(Nc3ccc(C(=O)O)cc3C)nc1-2

nearest known ligand 0.73

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TTK P33981 20/20 0.73
AURKA O14965 10/20 0.73
PLK1 P53350 3/20 0.72
CCNA2 P20248 2/20 0.72
CDK2 P24941 2/20 0.72
CCNA1 P78396 2/20 0.72
CSNK2A2 P19784 1/20 0.65
CSNK2B P67870 1/20 0.65
CSNK2A1 P68400 1/20 0.65
MELK Q14680 1/20 0.65
CSNK2A3 Q8NEV1 1/20 0.65
NEK6 Q9HC98 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1560138 0.93 TTK (0.82) TTKAURKAPLK1CCNA2CDK2
SCHEMBL1559095 0.90 TTK (0.88) TTKAURKAPLK1CCNA2CDK2
SCHEMBL1560061 0.90 TTK (0.69) TTKAURKAPLK1CCNA2CDK2
SCHEMBL1559201 0.89 TTK (0.84) TTKAURKAPLK1CCNA2CDK2
SCHEMBL1896096 0.88 TTK (0.84) TTKAURKAPLK1CCNA2CDK2
SCHEMBL12698456 0.88 TTK (0.84) TTKAURKAPLK1CCNA2CDK2
SCHEMBL1889499 0.86 TTK (0.86) TTKAURKAPLK1CCNA2CDK2
SCHEMBL1559656 0.86 TTK (0.71) TTKAURKAPLK1CCNA2CDK2
SCHEMBL15377726 0.85 TTK (0.81) TTKAURKAPLK1CCNA2CDK2
Trifluoroacetic Acid SCHEMBL15377596 0.84 TTK (0.79) TTKAURKAPLK1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2303891-B1 PYRAZOLO-QUINAZOLINES AS PROTEIN KINASE ACTIVITY MODULATORS SERVIER LAB (FR) 2016-02-17 EP claimed
US-8846701-B2 Pyrazolo-quinazolines NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-09-30 US claimed
US-20110105542-A1 PYRAZOLO--QUINAZOLINES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-05 US claimed
EP-2303891-A1 PYRAZOLO-QUINAZOLINES Nerviano Medical Sciences S.r.l. (IT) 2011-04-06 EP claimed
WO-2009156315-A1 PYRAZOLO-QUINAZOLINES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-12-30 WO claimed
EP-2303891-B1 PYRAZOLO-QUINAZOLINES AS PROTEIN KINASE ACTIVITY MODULATORS SERVIER LAB (FR) 2016-02-17 EP disclosed
US-8846701-B2 Pyrazolo-quinazolines NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-09-30 US disclosed
US-20110105542-A1 PYRAZOLO--QUINAZOLINES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-05 US disclosed
EP-2303891-A1 PYRAZOLO-QUINAZOLINES Nerviano Medical Sciences S.r.l. (IT) 2011-04-06 EP disclosed
WO-2009156315-A1 PYRAZOLO-QUINAZOLINES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105542-A1 PYRAZOLO--QUINAZOLINES PDXK, MAP4K5, MAP3K1 TTK 8/4885AURKA 370/4885PLK1 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.